A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

Objective: To evaluate the gastrointestinal safety and efficacy of the COX inhibiting nitric oxide donator AZD3582 in patients with hip or knee osteoarthritis. Methods: 970 patients were randomised (7:7:2) to AZD3582 750 mg twice daily, naproxen 500 mg twice daily, or placebo twice daily in a double...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Lohmander, L, McKeith, D, Svensson, O, Malmenas, M, Bolin, L, Kalla, A, Genti, G, Szechinski, J, Ramos-Remus, C, t for
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2005
Onderwerpen:
Extended Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1755403/
https://ncbi.nlm.nih.gov/pubmed/15345500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2004.023572
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items